Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

17.39 +0.42 (+2.47%)
Streaming Delayed Price Updated: 1:25 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 Next >
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum
Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance. 
Via Chartmill
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies. 
Via Benzinga
3 Biotech Catalysts Present Major Opportunity
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors. 
Via Chartmill
Arcutis (ARQT) Q2 Revenue Soars 164%
Via The Motley Fool
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected
Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings. 
Via Chartmill
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis
Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema. 
Via Benzinga
Analyst Expectations For Arcutis Biotherapeutics's Future
 
Via Benzinga
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick?
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing? 
Via Chartmill
4 Analysts Have This To Say About Arcutis Biotherapeutics
 
Via Benzinga
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
 
Via Benzinga
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
 
Via Benzinga
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews
 
Via Benzinga
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move
A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500. 
Via Talk Markets
Topics Stocks Stocks / Equities
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
 
Via Benzinga
How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy?
A fundamental and technical analysis of (NASDAQ:ARQT): Why ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) is Poised for High Growth. 
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your... 
Via Benzinga
What's Going On With Arcutis Biotherapeutics Stock Monday?
Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis. 
Via Benzinga
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter. 
Via Stocktwits
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
 
Via Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
 
Via Benzinga
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.